Stockscreener 앱 받기
7.75
2.02%
-0.16
시간 외 거래:
7.54
-0.21
-2.71%
Bluebird Bio Inc 주식(BLUE)의 최신 뉴스
bluebird bio (NASDAQ:BLUE) Share Price Passes Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Sickle Cell Treatment Market Focusing on Trends and Innovations - openPR
bluebird bio Q4 EPS Estimate Increased by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts bluebird bio FY2025 Earnings - MarketBeat
Sickle Cell Disease Pipeline 2024: Comprehensive Clinical - openPR
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD - MSN
Cantor Fitzgerald Estimates bluebird bio FY2025 Earnings - MarketBeat
Long-Term Investors in bluebird bio Inc (NASDAQ: BLUE) should - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Short Interest Update - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Adrenoleukodystrophy Drugs Market Is Booming Worldwide - openPR
Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $49.14 - Defense World
FDA investigating safety risks of bluebird's Skysona - MSN
bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
National Resilience to lay off 120 in North Carolina - Manufacturing Dive
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock By Investing.com - Investing.com Nigeria
Bluebird bio chief medical officer sells $175 in stock By Investing.com - Investing.com Australia
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock - Investing.com
Bluebird bio chief medical officer sells $175 in stock - Investing.com
bluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200-Day Moving AverageHere's Why - MarketBeat
Gene Therapy Market Generated Opportunities, Future Scope by 2031 | GlaxoSmithKline plc, Bluebird Bio, Inc. - openPR
Biotech manufacturer plans to cut 120 jobs in Durham - WRAL News
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Gene Therapy Market Generated Opportunities, Future Scope - openPR
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38% - Simply Wall St
Barclays Issues Positive Forecast for bluebird bio (NASDAQ:BLUE) Stock Price - Defense World
bluebird bio's SWOT analysis: gene therapy stock faces cash crunch amid launch - Investing.com
Barclays Forecasts Strong Price Appreciation for bluebird bio (NASDAQ:BLUE) Stock - MarketBeat
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
bluebird bio, Inc. (NASDAQ:BLUE) Sees Significant Decrease in Short Interest - MarketBeat
Once high-flying, bluebird bio now faces an uncertain future - The Business Journals
Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy - GlobeNewswire Inc.
Five things you need to know, and baby mind control - The Business Journals
Bluebird Bio (BLUE) Shares Surge Amid Market Activity - GuruFocus.com
2seventy bio: All In On ABECMA Multiple Myeloma Treatment - Seeking Alpha
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Gene Therapy For Rare Disease Market Overall Study Report - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gene Therapy Market Huge Growth in Future Scope 2024-2031 | - openPR
Baird cuts bluebird bio price target on near-term dilution By Investing.com - Investing.com Canada
bluebird bio (NASDAQ:BLUE) Shares Up 15.3%Time to Buy? - MarketBeat
Baird cuts bluebird bio price target on near-term dilution - Investing.com
Cell and Gene Therapy Drug Delivery Devices Market to Witness - openPR
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch By Investing.com - Investing.com South Africa
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch - Investing.com
3.95%
2.39%
자본화:
|
볼륨(24시간):